Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.P2D Bioscience has received the US and Canadian patent protection for its lead compounds PD2005 and PD2007 to treat attention deficit/hyperactivity disorder (ADHD).
Subscribe to our email newsletter
The patents contain ADHD-use claims for the entire family of P2D’s first-in-class dopamine transport inhibitors, including PD2005 and PD2007.
Initial studies indicate that P2D’s lead compounds are as effective as current first-line ADHD treatments in preclinical ADHD models.
Additionally, preclinical studies indicate that P2D’s lead compounds demonstrate reduced side effects, the primary criticism of existing first-line treatments.
P2D CEO Frank Zemlan said they believe that the combination of P2D’s improved patent position and preclinical studies demonstrates efficacy and limited side effects places them to develop a novel safe and effective ADHD treatment.
In addition to the US and Canadian patents, patent protection for P2D’s family of ADHD compounds is being prosecuted internationally.